Osman, Iman

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics

Hippo pathway signaling and YAP/TAZMelanoma and MAPK Pathways

Cited by 551

Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment

Barkley, D., Moncada, R., Pour, M., Liberman, D. A., Dryg, I., Werba, G., Wang, W., Baron, M., Rao, A., Xia, B., et al. (2022) · Nature Genetics

Single-cell and spatial transcriptomicsCancer Genomics and Diagnostics

Cited by 532

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Kugel, C. H., Douglass, S. M., Webster, M. R., Kaur, A., Liu, Q., Yin, X., Weiss, S. A., Darvishian, F., Al-Rohil, R. N., Ndoye, A., et al. (2018) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 367

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

Peters, B. A., Wilson, M., Moran, U., Pavlick, A., Izsak, A., Wechter, T., Weber, J. S., Osman, I., & Ahn, J. (2019) · Genome Medicine

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 263

Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells

Doudican, N., Rodriguez, A., Osman, I., & Orlow, S. J. (2008) · Molecular Cancer Research

Cell death mechanisms and regulationMelanoma and MAPK Pathways

Cited by 152

The ongoing racial disparities in melanoma: an analysis of the Surveillance, Epidemiology, and End Results database (1975-2016)

Qian, Y., Johannet, P., Sawyers, A., Yu, J., Osman, I., & Zhong, J. (2021) · Journal of the American Academy of Dermatology

Cutaneous Melanoma Detection and ManagementGlobal Cancer Incidence and Screening

Cited by 137